|
Paul F. Reid, PhD. is a Co-Founder of ReceptoPharm. From 1996 to May of 2001, Dr. Reid was an independent consultant to several privately held biotech companies where he used his expertise to assist in corporate development, strategic planning which included writing business plans, estimating market valuations for targeting potential venture capital and corporate partners, and making presentations to U.S. and European financial institutions. Dr. Reid also advised his clients regarding human and veterinary regulatory affairs for the United States, Canada, and Europe, and drug applications (pre IND, IND and Orphan), drug production, new drug development, clinical trial design, patient monitoring, and experimental design. From 1993 to 1996 Dr. Reid was employed by the United States Medical Research Institute for Infectious Diseases (USMRIID) at Fort Detrick, Maryland, under a grant from the National Research Council in Washington, D.C. Under the grant he was responsible for the expression and purification of a variety of neuroactive components from snake venom in bacterial and yeast systems and purification of expressed material with expansion to large-scale vaccine production. From 1991 to 1993, Dr. Reid was employed as a Post-Doctoral Researcher at Public Health Laboratories in Port Down, England, and Ruhr University in Bochum, Germany, where he was responsible for converting the laboratory to the utilization of genetic techniques. Dr. Reid's Ph.D. studies centered on investigating the activity and function of neural ion channels. Dr. Reid has a Bachelor's Degree in Microbiology from Trinity College in Dublin, Ireland and his Ph.D. is in Neurobiochemistry from Imperial College in London, England. In addition, Dr. Reid has completed FDA courses in current good manufacturing practices (cGMP/cGLP) and the preparation of standard operating procedures (SOPs) in accordance with government guidelines. | 